Preparation of integrin α(v) β(3)-targeting Ab 38C2 constructs

被引:24
作者
Sinha, Subhash C. [1 ]
Das, Sanjib [1 ]
Li, Lian-Sheng [1 ]
Lerner, Richard A. [1 ]
Barbas, Carlos F., III [1 ]
机构
[1] Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1038/nprot.2007.3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This protocol describes the preparation of Ab constructs using agents that target cells expressing integrins alpha(v)beta(3) and alpha(v)beta(5), and the monoclonal aldolase Ab 38C2. The targeting agents are equipped with a diketone or vinylketone linker, and selectively react through the reactive Lys residues in the Ab binding sites to form 38C2 conjugates or chemically programmed 38C2 (i.e., cp38C2). The targeting agent possessing a diketone linker reacts with the Lys residues forming an enaminone derivative. By contrast, the vinylketone linker is used as the corresponding acetone adduct (i.e., a pro-vinylketone linker), and this pro-adapter undergoes a 38C2-catalyzed retro-aldol reaction to produce the vinylketone linker, which forms a Michael-type adduct with the Lys residues. The Ab construct formation is achieved in < 1 h for the diketone compounds at ambient temperature, and in 2-16 h using the pro-vinylketone linker at 37 degrees C. The 38C2 constructs are retargeted to cells over-expressing integrins, and are potential candidates for immunotherapy.
引用
收藏
页码:449 / 456
页数:8
相关论文
共 13 条
[1]  
DOPPALAUDI VR, 2006, BIOORG MED CHEM LETT, V17, P501
[2]   Nonpeptide αvβ3 antagonists.: 1.: Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist [J].
Duggan, ME ;
Duong, LT ;
Fisher, JE ;
Hamill, TG ;
Hoffman, WF ;
Huff, JR ;
Ihle, NC ;
Leu, CT ;
Nagy, RM ;
Perkins, JJ ;
Rodan, SB ;
Wesolowski, G ;
Whitman, DB ;
Zartman, AE ;
Rodan, GA ;
Hartman, GD .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3736-3745
[3]   Breaking the one antibody-one target axiom [J].
Guo, Fang ;
Das, Sanjib ;
Mueller, Barbara M. ;
Barbas, Carlos F., III ;
Lerner, Richard A. ;
Sinha, Subhash C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (29) :11009-11014
[4]   Therapeutic antibodies -: Delivering the promise? [J].
Hale, Geoff .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) :633-639
[5]  
KOHZOH I, 2006, NAT REV CANCER, V6, P714
[6]   Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics [J].
Kok, RJ ;
Schraa, AJ ;
Bos, EJ ;
Moorlag, HE ;
Asgeirsdóttir, SA ;
Everts, M ;
Meijer, DKF ;
Molema, G .
BIOCONJUGATE CHEMISTRY, 2002, 13 (01) :128-135
[7]   Chemical adaptor immunotherapy: Design, synthesis, and evaluation of novel integrin-targeting devices [J].
Li, LS ;
Rader, C ;
Matsushita, M ;
Das, S ;
Barbas, CF ;
Lerner, RA ;
Sinha, SC .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (23) :5630-5640
[8]   Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis [J].
List, B ;
Barbas, CF ;
Lerner, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15351-15355
[9]   Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice [J].
Lu, Yingjuan ;
Xu, Le-Cun ;
Parker, Nikki ;
Westrick, Elaine ;
Reddy, Joseph A. ;
Vetzel, Marilynn ;
Low, Philip S. ;
Leamon, Christopher P. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (12) :3258-3267
[10]   Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector [J].
Popkov, Mikhail ;
Rader, Christoph ;
Gonzalez, Beatriz ;
Sinha, Subhash C. ;
Barbas, Carlos F., III .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) :1194-1207